Menu Close
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech
An Official Publication of
  • Clinical
    • In the Literature
    • Key Clinical Questions
    • Interpreting Diagnostic Tests
    • Coding Corner
    • Clinical
    • Clinical Guidelines
    • COVID-19
    • POCUS
  • Practice Management
    • Quality
    • Public Policy
    • How We Did It
    • Key Operational Question
    • Technology
    • Practice Management
  • Diversity
  • Career
    • Leadership
    • Education
    • Movers and Shakers
    • Career
    • Learning Portal
    • The Hospital Leader Blog
  • Pediatrics
  • HM Voices
    • Commentary
    • In Your Eyes
    • In Your Words
  • SHM Resources
    • Society of Hospital Medicine
    • Journal of Hospital Medicine
    • SHM Career Center
    • SHM Converge
    • Join SHM
    • Converge Coverage
    • SIG Spotlight
    • Chapter Spotlight
    • #JHM Chat
  • Industry Content
    • Patient Monitoring with Tech

Mitchel L. Zoler, PhD

  • 1
    News

    SGLT2 inhibitor use tied to fewer atrial arrhythmias

    December 2, 2021

    A prospective study of nearly 14,000 patients who received an implantable cardiac device suggests that SGLT2-inhibitor treatment cuts atrial arrhythmias.

  • News

    Advanced CKD doesn’t derail empagliflozin in EMPEROR-preserved

    November 19, 2021

    Study shows empagliflozin led to a consistent, significant relative risk reduction compared with placebo in the primary endpoint.

  • 1
    News

    EMPEROR-Preserved findings confirmed in ‘true’ HFpEF patients

    November 17, 2021

    A landmark trial proved empagliflozin’s efficacy in HFpEF, but many patients had “moderately reduced” EFs. The findings hold up even without them.

  • 1
    News

    EMPEROR-Preserved: Empagliflozin’s HFpEF efficacy catalyzes a heart failure redefinition

    September 20, 2021

    Cardiologists have long defined heart failure as involving reduced or preserved ejection fraction. Results from big empagliflozin trials say forget that.

  • 1
    News

    PRESERVED-HF: Dapagliflozin improves physical limitations in patients with HFpEF

    September 14, 2021

    The SGLT2 inhibitor dapagliflozin boosted KCCQ scores and 6-minute walk distance in HFpEF patients in a 324-patient randomized trial.

  • 1
    News

    EMPEROR-Preserved spouts torrent of reports on empagliflozin treatment of HFpEF

    August 31, 2021

    The primary report from EMPEROR-Preserved on using empagliflozin to treat patients with HFpEF arrived with four other analyses published in its wake.

  • 1
    News

    EMPEROR-Preserved: Empagliflozin scores HFpEF breakthrough

    August 27, 2021

    Empagliflozin is the first treatment to produce an unequivocal, hard-endpoint benefit in patients with heart failure with preserved ejection fraction, a practice-changing result.

  • News

    U.S. kidney transplants grow in number and success

    August 24, 2021

    Data from 1996 to 2019 show more U.S. kidney transplants recently than ever before, and steady improvements in graft and patient survival.

  • 1
    News

    SGLT2 inhibitor use rising in patients with DKD

    August 23, 2021

    Use of SGLT2 inhibitors in patients with type 2 diabetes rose sharply in 2019 and early 2020. GLP-1 RA use also showed recent gains.

  • News

    Empagliflozin gets HFrEF approval from FDA

    August 19, 2021

    The SGLT2 inhibitor empagliflozin (Jardiance) becomes the second agent from this class to get a heart failure indication regardless of diabetes status.

1 2 3 … 12Next
  • About The Hospitalist
  • Contact Us
  • The Editors
  • Editorial Board
  • Authors
  • Publishing Opportunities
  • Subscribe
  • Advertise
fa-facebookfa-linkedinfa-instagramfa-youtube-playfa-commentfa-envelopefa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies.
    ISSN 1553-085X
  • Privacy Policy
  • Terms and Conditions
  • SHM’s DE&I Statement
  • Cookie Preferences